Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

2010

 
11.10.2010
Antitope Announces EpiScreen Collaboration with Chugai
October 2010 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with Chugai Pharmaceuticals Co., Ltd of Tokyo, Japan ("Chugai") whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of therapeutic...
11.10.2010
Meet Antitope at BIO-Europe 2010 (Munich Germany 15th-17th November)
Antitope will be participating in the Business Partnering Forum at the BIO Europe Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged through the...
29.09.2010
Antitope Announces EpiScreen Collaboration with Abraxis
Antitope Ltd., Cambridge UK (“Antitope”) today announced a they will be providing immunogenicity evaluation services for Abraxis BioScience LLC, Los Angeles, USA ("Abraxis") whereby Antitope will apply its proprietary EpiScreenTM technology to analyse the immunogenicity...
25.08.2010
Antitope Announces Research Collaboration with Ablynx
25 August 2010 - Antitope Ltd. of Cambridge UK (“Antitope”) today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx") whereby Antitope will apply its proprietary EpiScreenTM technology to profile a series of Nanobodies® developed by Ablynx for...
19.07.2010
Antitope Announces EpiScreen Collaboration with PIKAMAB
19 July 2010 - Antitope Ltd. today announced a research collaboration with PIKAMAB, Inc. ("PIKAMAB") whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of a series of biologics developed by PIKAMAB for the personalized treatment of...
09.06.2010
Antitope Announces EpiScreen Collaboration with Zyngenia
Antitope Ltd. today announced a research collaboration with Zyngenia, Inc. ("Zyngenia") whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of a series of therapeutic ZybodyTM molecules being developed by Zyngenia to address multiple biological...
19.05.2010
Antitope Announces EpiScreen™ Collaboration with Daiichi Sankyo to Analyze Immunogenicity in Therapeutic Antibodies
Antitope Ltd. ("Antitope") today announced a research collaboration with the Japanese multinational pharmaceutical company Daiichi Sankyo Company Limited ("Daiichi Sankyo") in which Antitope will apply its proprietary EpiScreen™ technology to analyze the immunogenicity of...
08.04.2010
Antitope announces initiation of anti-Clever-1 antibody humanization in collaboration with Faron
Antitope Ltd. ("Antitope") today announced a research agreement with Faron Pharmaceuticals Ltd. ("Faron") for the generation of therapeutic monoclonal antibodies against Clever-1 receptor. Under the Agreement, Antitope will apply its proprietary Composite Human Antibody™...
23.03.2010
Antitope Ltd. and Cantab Biopharmaceuticals Enter into a Research Agreement
23rd March 2010 - Antitope Ltd. (UK) today announced a research agreement with Cantab Biopharmaceuticals Ltd (Cambridge, UK) for the development of a biosuperior protein therapeutic in the area of haematology. As part of the agreement, Antitope will apply its proprietary technologies towards...
23.02.2010
Meet Antitope at BIO Europe 2010 (Barcelona, Spain 8th - 10th March)
Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged...
26.01.2010
Antitope Ltd. today announced a research agreement with Agence Nationale de Recherches sur le SIDA et les hepatitives virales (ANRS, France), INSERM (France) and Baylor Research Institute (BRI, Dallas, Texas USA)
Cambridge UK, January 2010 - Antitope Ltd. today announced a research agreement with Agence Nationale de Recherches sur le SIDA et les hepatitives virales (ANRS, France), INSERM (France) and Baylor Research Institute (BRI, Dallas, Texas USA) for the generation of multiple humanized antibodies....
26.01.2010
Antitope Announces Research Agreement with Emory University
26th January 2010 - Antitope Ltd. (UK) today announced a research agreement with Emory University, Atlanta (USA) for the development of an antibody therapeutic for H1N1 influenza (‘swine flu’) generated through a collaboration between researchers at Emory University and the University...